Literature DB >> 23202802

Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.

Jing Li1, Yun Du, Xian Liu, Qian-cheng Shen, Ai-long Huang, Ming-yue Zheng, Xiao-min Luo, Hua-liang Jiang.   

Abstract

AIM: To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV).
METHODS: Computational approaches, including homology modeling, docking, MD simulation and MM/PBSA free energy analyses were used.
RESULTS: Sequence analyses revealed that residue 238 near the binding pocket was not only a polymorphic site but also a genotype-specific site (His238 in genotype B; Asn238 in genotype C). The calculated binding free-energy supported the hypothesis that the polymerase from HBV genotype C was more sensitive to ADV than that from genotype B. By using MD simulation trajectory analysis, binding free energy decomposition and alanine scanning, some energy variation in the residues around the binding pocket was observed. Both the alanine mutations at residues 236 and 238 led to an increase of the energy difference between genotypes C and B (ΔΔG(C-B)), suggesting that these residues contributed to the genotype-associated antiviral variability with regard to the interaction with ADV.
CONCLUSION: The results support the hypothesis that the HBV genotype C polymerase is more sensitive to ADV than that from genotype B. Moreover, residue N236 and the polymorphic site 238 play important roles in contributing to the higher sensitivity of genotype C over B in the interaction with ADV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23202802      PMCID: PMC4011611          DOI: 10.1038/aps.2012.146

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  43 in total

Review 1.  Do we need to determine viral genotype in treating chronic hepatitis B?

Authors:  W G E Cooksley
Journal:  J Viral Hepat       Date:  2010-05-31       Impact factor: 3.728

2.  Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.

Authors:  Soo-Yon Rhee; Severine Margeridon-Thermet; Mindie H Nguyen; Tommy F Liu; Ron M Kagan; Bastian Beggel; Jens Verheyen; Rolf Kaiser; Robert W Shafer
Journal:  Antiviral Res       Date:  2010-09-25       Impact factor: 5.970

3.  The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

Authors:  Nadia Warner; Stephen Locarnini; Michael Kuiper; Angeline Bartholomeusz; Anna Ayres; Lilly Yuen; Tim Shaw
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

4.  Inhibition of hepatitis B virus polymerase by entecavir.

Authors:  David R Langley; Ann W Walsh; Carl J Baldick; Betsy J Eggers; Ronald E Rose; Steven M Levine; A Jayne Kapur; Richard J Colonno; Daniel J Tenney
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 5.  Is response to antiviral treatment influenced by hepatitis B virus genotype?

Authors:  Sara Raimondi; Patrick Maisonneuve; Savino Bruno; Mario U Mondelli
Journal:  J Hepatol       Date:  2010-01-06       Impact factor: 25.083

6.  Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.

Authors:  Pankaj R Daga; Jinsong Duan; Robert J Doerksen
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

7.  Hepatitis B virus genotype-associated variability in antiviral response to adefovir dipivoxil therapy in Chinese Han population.

Authors:  Ai-Zhong Zeng; Hui Deng; Chung Yang; Xiao-Juan Xin; Qing-Ling Li; Jin-Jun Guo; Ping Lu; Ai-Long Huang
Journal:  Tohoku J Exp Med       Date:  2008-11       Impact factor: 1.848

8.  Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.

Authors:  Fabien Zoulim; Parviz Parvaz; Patrick Marcellin; Jean-Pierre Zarski; Michel Beaugrand; Yves Benhamou; François Bailly; Marianne Maynard; Christian Trepo; Aldo Trylesinski; Françoise Monchecourt
Journal:  Liver Int       Date:  2008-09-15       Impact factor: 5.828

9.  Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

Authors:  Bao-Ming Liu; Tong Li; Jie Xu; Xiao-Guang Li; Jian-Ping Dong; Ping Yan; Jing-Xian Yang; Ling Yan; Zhi-Yong Gao; Wen-Peng Li; Xie-Wen Sun; Yu-Hua Wang; Xiu-Juan Jiao; Chun-Sheng Hou; Hui Zhuang
Journal:  Antiviral Res       Date:  2009-12-23       Impact factor: 5.970

10.  Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.

Authors:  X Wang; W Yang; X Xu; H Zhang; Y Li; Y Wang
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

View more
  4 in total

1.  Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors.

Authors:  Xian-qiang Sun; Lei Chen; Yao-zong Li; Wei-hua Li; Gui-xia Liu; Yao-quan Tu; Yun Tang
Journal:  Acta Pharmacol Sin       Date:  2013-12-16       Impact factor: 6.150

2.  Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1.

Authors:  Shi-En Liu; Jun-Chi Hu; Hao Zhang; Pan Xu; Wei Wan; Ming-Yue Zheng; Kun-Qian Yu; Hong Ding; Hua-Liang Jiang; Lu Zhou; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2017-07-27       Impact factor: 6.150

3.  Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.

Authors:  Yue Zhou; Na Zhang; Shan Tang; Xiaoqian Qi; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

4.  Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.

Authors:  Sung Hyun Ahn; Doo Hyun Kim; Ah Ram Lee; Beom Kyung Kim; Yong Kwang Park; Eun-Sook Park; Sang Hoon Ahn; Gu-Choul Shin; Soree Park; Hong Seok Kang; Jin-Kyu Rhee; Sung-Il Yang; Youhoon Chong; Kyun-Hwan Kim
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.